Diagnostic mutational analysis of MECP2 in Korean patients with Rett syndrome by 源��씎�룞
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 38, No. 2, 119-125, April 2006
In-Joo Kim1, Yeon-Joo Kim2,
Byeong-Hee Son5, Sang-Ook Nam3,
Hoon-Chul Kang6, Heung-Dong Kim7,
Mi-Ae Yoo8, Ook-Hwan Choi2,9,10  
and Cheol-Min Kim1,4,9,11
1Department of Biochemistry
2Department of Obstetrics and Gynecology
3Department of Pediatrics
4Biomedical Informatics Unit, College of Medicine
Pusan National University
Busan 602-739, Korea
5Department of Pediatrics, St. Benedict Hospital
Busan 601-731, Korea
6Department of Pediatrics, Epilepsy Center
College of Medicine, Inje University
Sang-gye Paik Hospital
Seoul 139-707, Korea
7Department of Pediatrics
College of Medicine, Yonsei University
Severance Hospital, Handicapped Children's Research Institute
Brain Research Institute
Seoul 139-707, Korea
8Department of Molecular Biology
College of Natural Science, Pusan National University
Busan 609-735, Korea
9Medical Research Institute
Pusan National University Hospital
Busan 602-739, Korea
10Co-corresponding author: E-mail, ohchoi@pusan.ac.kr
11Corresponding author: Tel, 82-51-240-7725;
Fax, 82-51-248-1118; E-mail, kimcm@pusan.ac.kr
Accepted February 20 2006
Abbreviations: HDAC, histone deacetylases; MBD, methyl-CpG 
binding domain; MECP2, methyl-CpG binding protein 2; NLS, nuclear 
localization signal; RTT, Rett syndrome; SNP, single nucleotide 
polymorphism; TRD, transcriptional repression domain; WDR, group 
II WW domain binding region
Abstract
Rett syndrome (RTT) is an X-linked dominant 
neurodevelopmental disorder affecting 1 per 10,000- 
15,000 female births worldwide. The disease-cau -
sing gene has been identified as MECP2 (methyl- 
CpG-binding protein 2). In this study, we performed  
diagnostic mutational analysis of the MECP2 gene in  
RTT patients. Four exons and a putative promoter of 
the MECP2 gene were analyzed from the peripheral 
blood of 43 Korean patients with Rett syndrome by 
PCR-RFLP and direct sequencing. Mutations were  
detected in the MECP2 gene in approximately 60.5%  
of patients (26 cases/43 cases). The mutations  
consisted of 14 different types, including 9 missense  
mutations, 4 nonsense mutations and 1 frameshift 
mutation. Of these, three mutations (G161E, T311M, 
p385fsX409) were newly identified and were deter-
mined to be disease-causing mutations by PCR- 
RFLP and direct sequencing analysis. Most of the  
mutations were located within MBD (42.3%) and TRD  
(50%). T158M, R270X, and R306C mutations were  
identified at a high frequency. Additionally, an  
intronic SNP (IVS3 + 23C＞G) was newly identified in  
three of the patients. IVS3 + 23C＞G may be a  
disease-related and Korea-specific SNP for RTT. 
L100V and A201V are apparently disease-causing  
mutations in Korean RTT, contrary to previous  
studies. Disease-causing mutations and polymor-
phisms are important tools for diagnosing RTT in  
Koreans. The experimental procedures used in this  
study should be considered for clinical molecular 
biologic diagnosis. 
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Introduction
Rett syndrome (RTT, MIM No. 312750) is an 
X-linked dominant neurodevelopmental disorder and 
is the second most common cause of mental 
retardation in females, following Down syndrome 
(Rett, 1966; dos Santos et al., 2005). The vast 
majority of cases of RTT (more than 99%) are 
sporadic occurrences and familial recurrences are 
rare (Hoffbuhr et al., 2001). 
    RTT is caused by mutations in a gene encoding 
the methyl-CpG binding protein 2 (MECP2, AF30876) 
(Amir et al., 1999). MECP2 is mapped between 
IRAK (interleukin-1 receptor associated kinase) and 
RCP (red opsin gene) loci on chromosome Xq28 
(Reichwald et al., 2000). It is 76 kb in size and is 
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composed of 486 amino acids. The four exons of 
human MECP2 have a combined length of 1775 bp. 
MECP2 participates in transcriptional silencing by 
binding to methylated DNA in nucleosomes and 
chromatin. It contains functional domains, a me-
thyl-CpG binding domain (MBD) of 85 amino acids 
that binds to methylated CpG islands, and a 
transcriptional repression domain (TRD) of 104 
amino acids that interacts with the transcriptional 
repressor Sin3A, which recruits histone deacety-
lases (HDAC) (Van den Veyver and Zoghbi, 2000). 
In addition, MECP2 has a nuclear localization signal 
(NLS) (Jorgensen and Bird, 2002) and a group II 
WW domain binding region (WDR) (Buschdorf and 
Stratling, 2004; Weaving et al., 2005). The function 
of NLS within the TRD location is to facilitate the 
transport of MECP2 into the nucleus. 
    There are only a few reports regarding muta-
tional analysis of MECP2 in Koreans because the 
overall understanding of RTT is limited (Chae et al., 
2002). To compare the pattern of MECP2 mutations 
in Koreans with RTT from worldwide reports, we 
performed mutational analysis in Korean RTT 
patients and control subjects. Direct DNA sequenc-
ing was used and results were confirmed by 
PCR-RFLP. 
Materials and Methods 
DNA samples from RTT patients  
Whole blood samples (500 µl) from 43 sporadic RTT 
patients (41 females and 2 males) were collected in 
EDTA tubes. All patients were phenotypically cla-
ssical RTT. Genomic DNA was extracted using an 
E.Z.N.A. blood DNA kit (Omega Bioteck Inc. 
Norcross). 
PCR amplification
The putative promoter and four exons of the MECP2 
gene were amplified by PCR by dividing exon 2 into 
two parts, exon 3 into two parts, and exon 4 into five 
parts. Primer sequences designed by Amir et al. 
(1999) were used, except for the putative promoter 
and exon 1. The sequence of the promoter and exon 
1 were 5'-gggTgCAATgAAACgCTTA-3' (forward) and 
5'-TTTACCACAgCCCTCTCTCC-3' (reverse).
Direct sequencing  
The PCR products were cleaned using a QIAquick 
gel extraction kit (QIAGEN, Hiden, Germany). The 
sequencing primers were the same as those for 
PCR. The DNA sequencing results were compared 
with the normal DNA sequence (AF030876). 
RFLP analysis  
We used the GeneTyx program to investigate the 
restriction enzyme sites. Dde I (New England Bio-
labs Co., MA) was used to detect G161E. BsmB I 
(New England Biolabs.) was used to detect T311M. 
A mismatch PCR technique was used to determine if 
the L100V is a disease-causing mutation. A second 
new reverse primer of exon 3 for the L100V mutation 
was designed (5'-GCTTAAGCTTCCGTGTCCAGC-
CTTCAGGTA-3'). The primer sequence for mis-
match PCR is underlined. The PCR product for 
Figure 1. Distribution of MECP2
mutations in RTT. Top: Mutations 
identified in this study. Novel mu-
tations are indicated by bold un-
derlined type. Bottom: mutations 
described previously (MECP2 va-
riation database of InterRETT 
and RettBASE) (Fyfe et al., 
2003). Circles (○,  ) represent 
missense mutations and squares 
( ,   ) represent nonsense mu-
tations. Mutations at CpG dinu-
cleotides are shown by filled cir-
cles (   ) or squares (   ). Fre-
quency is indicated by the num-
ber of symbols (Buyse et al., 
2000; Miltenberger-Miltenyi and 
Laccone, 2003; Fukuda et al., 
2005; Oexle et al., 2005).
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L100V in the MECP2 gene created an Afa I (Takara, 
Tokyo, Japan) restriction site. A201V created a Bal I 
(Takara) restriction site. Restriction digested pro-
ducts were separated by electrophoresis on either 
2% agarose gel or 4% NuSieve gel (FMC, Rockland) 
(Bedia et al., 2003; Kim et al., 2004).
Results
Mutational analysis of MECP2
To investigate mutation of the MECP2 gene, we 
analyzed a promoter and four exons of MECP2 in 43 
RTT patients by direct sequencing. The amplified 
PCR product contained an intron and an exon. 
MECP2 mutations were detected in 26 (60.5%) of 
the 43 patients. These results were compared with 
the MECP2 variation database for InterRETT and 
RettBASE (Fyfe et al., 2003). The mutations con-
sisted of 14 different types, including 9 missense 
mutations, 4 nonsense mutations, and 1 frameshift 
mutation. Most of these mutations were located 
within MBD (42.3%) and TRD (50%) (Figure 1). Of 
the mutations identified, three (G161E, T311M, 
P385fsX409) were new (Figure 2). Three mutations, 
T158M (9.3%), R270X (11.6%), and R306C (7%), 
were identified with a high frequency (Table 1). The 
two male patients with different RTT phenotypes did 
not have any identifiable mutations. Two silent 
mutations (F142F, T442T) that had been reported 
previously (Miltenberger-Miltenyi and Laccone, 2003) 
were also found. These accompanied other muta-
tions in three of the four patients with F142F and 
T442T.
Confirmation of the mutations
To confirm the novel sequence changes, RFLP 
analysis was performed for G161E and T311A 
(Table 1) and direct sequencing was performed for 
p385fsX409. The G161E (c.482G＞A) mutation 
created a Dde I site while the wild type had 241 bp 
and 129 bp fragments, and the heterozygotic mutant 
had 241 bp, 202 bp, 129 bp, and 39 bp fragments 
(Figure 3A, lane 5 and 6). The T311A (c.932C＞T) 
mutation destroyed the BsmB I site. The 366 bp 
product was digested into 198 bp and 168 bp 
fragments in the wild type (Figure 3A, lane 8), 
whereas patients with T311A exhibited a single band 
Figure 2. DNA sequencing electropherograms of wild type (A) and novel mutations (B) of MECP2 identified in RTT patients in this study. 
Substituted nucleotides are indicated by arrows and substituted amino acids are underlined. Deletion sites are indicated by arrowheads. 
All sequences are in the sense orientation. The mutation P385fsX409 was identified by sequencing after cloning.
A
c.932G>T
p.G161E p.T311M p.P385fsX409
B
c.482G>A c.1153_1196del
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Table 1. Summary of MECP2 mutations and sequence variants in RTT patients 
Mutation type    Domain    Exon
Nucleotide 
changea
Amino acid 
changea Frequency
b Restriction
enzymee    Patients
Missense 
mutations
MBD
MBD
MBD
MBD
MBD
IDR
TRD
TRD
WDR, C-term.
Exon3(2)
Exon4(1)
Exon4(1)
Exon4(1)
Exon4(1)
Exon4(1)
Exon4(3)
Exon4(3)
Exon4(3)
c.298C＞ G
c.397C＞ T
c.468C＞ G
c.473C＞ T
c.482G＞ A
c.602C＞ T
c.916C＞ T
c.932C＞ T
c.965C＞ T
p.L100V
p.R133C
p.D156E
p.T158M
p.G161Ec
p.A201V
p.R306C
p.T311Mc
p.P322L
       2.3%
       4.7%
       2.3%
       9.3%
       2.3%
       2.3%
7.0%
       2.3%
       2.3%
Afa I(+)
Dde I(+)
Bal I(+)
BsmB I(-)
R21
R8, 35
R24
R6, 11, 12, 19
R13
R20
R4, 30, 33
R28
R16
Nonsense 
mutations
MBD
TRD
TRD, NLS
TRD
Exon4(1)
Exon4(2)
Exon4(3)
Exon4(3)
c.502C＞ T
c.763C＞ T
c.808C＞ T
c.880C＞ T
p.R168X
p.R255X
p.R270X
p.R294X
       4.7%
       4.7%
     11.6%
       2.3%
R5, 7
R9, 14
R15, 23, 25, 31, 38
R36
Frameshift WDR, C-term. Exon4(4) c.1153_1196del p.P385fsX409c        2.3% R37
Silent 
mutations
MBD
WDR, C-term.
Exon4(1)
Exon4(4)
c.426C＞ T
c.1326C＞ T
p.F142Fd
p.T442Td
       2.3%
7.0%
R4
R7, 17, 25
SNP Intron3 IVS3 + 23C＞G 7.0% R15, 24, 34
aNucleotides and amino acids are numbered according to GenBank. bFrequency of substitution among 43 Korean patients with classical RTT. cThree 
novel mutations were identified in this study. dThe nucleotide is substituted, but the amino acid is silent. eRestriction enzyme sites for RFLP analysis 
were created (+) or destroyed (-) by novel mutations and sequence variants of the MECP2 gene in RTT patients. The description of the sequence var-
iant was based on the work of den Dunner and Antonarakis (2000; 2001). The patients indicated by bold type exhibited two types of nucleotide 
changes.
Figure 3. RFLP for novel mutations (G161E, T311M) and unclassified variants (L100V, A201V). Gel electrophoresis of PCR products before (U, un-
cut) and after (C, cut) the restriction enzyme site. Cut samples are distinguished as normal controls (N) and as mutations in patients (P). (A) PCR 
product showing the part of exon 3 with a mismatch sequence (lane 1) and exon 4 (lane 4 and 7). The L100V mutation separated the 199 bp PCR 
product into 170 bp and 29 bp fragments by mutation-induced cleavage at the Afa I site. (lane 2 and 3) Dde I digestion created a 202 bp and a 39 bp 
fragment in G161E mutation (lane 5 and 6). T311M mutation identified by loss of the BsmB I site (lane 8 and 9). (B) A201V creates a Bal I restriction 
site. Normal controls have 279 bp products and are not cleaved by Bal I digestion, while patients with A201V generated 229 bp and 52 bp fragments. 
Lane M is a 100 bp molecular weight marker. The lower 60 bp products migrated off the gel.
M
A
U C
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U C
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C
(P)
U C
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C
(P)
M
L100V G161E T311M
400 bp
300 bp
200 bp
100 bp
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(366 bp) (Figure 3A, lane 9). The novel deletion 
mutation p385fsX409 (1153del44bp) was not identi-
fied by direct sequence mutational screening of exon 
4 in the control samples. All of these base sub-
stitutions were absent in more than 100 control 
individuals. The RFLP and direct sequencing data 
indicate that these DNA variants are potential 
disease-causing mutations. 
    L100V (c.298C＞G), one of these previously pre-
dicted substitutions, has been reported to be an 
unclassified variant associated with RTT (Buyse et 
al., 2000). Mismatch PCR was performed to 
determine whether L100V is also SNP in Korea. 
After amplification with the mismatch primers, the 
wild type sequence CCCTACCTGAA was genera-
ted. The generated mutant sequence CCG/TACCT-
GAA created an Afa I site. The 199 bp product was 
cut into pieces of 170 bp and 29 bp (Figure 3A, lane 
2 and 3). Additionally, A201V (c.602C＞T) has been 
reported to be a Japanese-specific characteristic 
because the mutation occurs in the normal Ja-
panese population (Fukuda et al., 2005). The 279 bp 
product with A201V was cut into 227 bp and 52 bp 
fragments by Bal I (Figure 3B, lane 2~10). L100V 
and A201V were absent in more than 100 normal 
control subjects and, therefore, were thought to be 
disease-causing mutations. 
Single nucleotide polymorphism (SNP) of the MECP2 
gene 
IVS3 + 23C＞G (g.C65494G) was observed in only 
three patients (7%) (Figure 4). The novel SNP 
accompanied other mutations in two of the patients.
Discussion  
In classical cases, the mutation rate approaches 
80% with lower rates in atypical cases (30%) 
(Hoffbuhr et al., 2001). There is no clear correlation 
between the type and position of mutations, although 
MECP2 plays a pivotal role in the RTT phenotype 
(Weaving et al., 2003). We identified mutations of 
the MECP2 gene in 60.5% (26/43 cases) of the 
patients (Table 1). The mutational frequency was 
lower in our results than in previous studies due to 
the inclusion of patients with various phenotypes of 
RTT, and not limiting subjects to classical cases, as 
in previous reports. Most mutations were identified in 
the functional domains (25/26, 96.2%) MBD, TRD 
and WDR, and, therefore, probably critically affect 
the function of MECP2. We identified three novel 
mutations that cause amino acid substitutions 
(G161E, T311M, P385fsX409). G161E was found in 
MBD, T311M in TRD, and P385fsX409 in WDR of 
the C-terminus. The G161E substitution resulted in 
an alteration of a charge from neutral to negative 
Figure 4. Single nucleotide poly-
morphism in the MECP2 gene 
identified by direct sequence 
analysis. (A) The substituted nu-
cleotide is indicated by an arrow 
and the substituted codon is 
marked by underlining. All sequ-
ences are in the sense ori-
entation. (B) Distribution of single 
nucleotide polymorphism in the 
MECP2 gene is identified. Top: 
The SNP identified in this study, 
Bottom: SNPs described by oth-
ers (Buyse et al., 2000; Fukuda 
et al., 2005).
Region :  A
B
Change:
Intron 3
IVS3 + 23C > G
Coding region
Methy1-CpG-binding domain
Transcriptional repression domain
NLS
WDR
SNP
Controls RTT patients
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and may reduce or abolish methyl-CpG binding. 
T311M probably causes the hydrophilic amino acid 
to be replaced by a hydrophobic one. P385fsX409 
results in a reduction or loss of WW domain binding 
activity. The truncated mutation probably causes 
loss of the splicing factors FBP11 and HYPC that 
normally interact with WDR (Buschdorf and Stratling, 
2004; Weaving et al., 2005). Hence, it may cause 
defective splicing that is involved with MECP2. 
These mutational results probably alter the pro-
perties of the protein. Twenty-two of the mutations 
(22/26, 84.6%) involved C→T transition at CpG dinu-
cleotides. A clustering of mutations was identified in 
exon 4, except for L100V (25/26, 96.2%). Our find-
ings strongly indicate that exon 4 should be se-
quenced first to screen for MECP2 mutations be-
cause the region is a hotspot for MECP2 mutations 
in RTT patients. Screening of two (exons 3 and 4) of 
the four exons will identify almost all gene mutations 
found in RTT patients, especially in Korean RTT 
patients.
    To predict whether the observed changes were 
mutations or polymorphism, PCR-RFLP analysis of 
G161E and T311M was performed. Direct se-
quencing was used to analyze P385fsX409. These 
mutations were not found in more than 100 control 
subjects. Therefore, G161E, T311M, and P385fsX409 
are probably disease-causing mutations. Previous 
studies reported that L100V and A201V are the 
unclassified sequence and the SNP (Buyse et al., 
2000; Fukuda et al., 2005), respectively. The alleles 
did not appear in more than 100 Korean control 
subjects. L100V and A201V were identified as possi-
ble disease-causing mutations from RFLP analysis 
in Korean RTT patients, which is contrary to 
previous reports. No mutation in MECP2 was found 
in the two male RTT patients in our study. Mutations 
in MECP2 in most males are lethal (Orrico et al., 
2000). The infrequent occurrence of RTT in males 
has been explained by the existence of somatic 
mosaicism for an RTT-causing MECP2 mutation 
(Jellinger, 2003). We identified two silent mutations 
(F142F, T442T) and an intronic SNP (IVS3 +
23C＞G) of the gene. The silent mutations are 
probably not responsible for the disease phenotype 
although they were associated with other mutations, 
except in one patient. IVS3 + 23C＞G was observed 
in only three RTT patients (7%) and was not ob-
served in control subjects. It is possible that IVS3 +
23C＞G is a disease-related and Korea-specific 
SNP for RTT. The novel SNP accompanied other 
mutations in two of the patients. This polymorphism 
probably results in phenotypic variability or suscep-
tibility to RTT, even though it is an intronic SNP.
    Mutation in MECP2 is not synonymous with RTT, 
and RTT is not always caused by an identifiable 
mutation in MECP2 (Miltenberger-Miltenyi and La-
ccone, 2003). Recently, studies have suggested a 
relationship between RTT and MECP2 in the re-
gulation of UBE3A (Ubiquitin-Protein ligase E3A), 
GABRB3 (the beta3 subunit of the GABAA receptor) 
and CDKL5 (Cyclin-dependent kinase-like5) expre-
ssion (Fan G and Hutnick L, 2005; Milani et al., 
2005; Samaco et al., 2005; Segawa and Nomura, 
2005). In this study, we did not detect any mutations 
of MECP2 in seventeen of the patients. These cases 
should be analyzed for mutations of other candidate 
genes, followed by functional analysis of these 
genes, as well as MECP2. 
    PCR-RFLP is an essential step in determining 
whether the observed changes to the MECP2 gene 
are mutations or polymorphisms. Disease-causing 
mutations and polymorphisms are important for 
diagnosing RTT in Koreans. The experimental pro-
cedures used in this study should be considered for 
molecular biologic diagnosis in the clinical field. 
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